{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "Johnson & Johnson", "item": "https://www.patentleaderboard.com/company/jnj"}, {"@type": "ListItem", "position": 3, "name": "Nathan Majewski", "item": "https://www.patentleaderboard.com/inventor/fl:na_ln:majewski-1"}]}
Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
NM

Nathan Majewski — 4 Patents

Johnson & Johnson: 4 patents #2,234 of 7,810Top 30%
NUNew York University: 1 patents #708 of 1,640Top 45%
Warrington, PA: #49 of 202 inventorsTop 25%
Pennsylvania: #19,360 of 74,527 inventorsTop 30%
Overall (All Time): #1,080,739 of 4,157,543Top 30%
4 Patents All Time
Nathan Majewski has been granted 4 US patents while listed as an inventor at Johnson & Johnson. The first was granted in 2020 and the most recent in January 2024. Nathan Majewski ranks #1,080,739 of 4,157,543 US inventors in our database (top 26.0%). Patent records list Nathan Majewski in Warrington, PA, US.

Patents per Year

Patents granted per year, 2020 to 2024Bar chart with a peak of 1 patents in 2020.peak 12020: 1 patents20202021: 1 patents20212023: 1 patents20232024: 1 patents2024

Issued Patents All Time

Showing 1–4 of 4 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
11884722 Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca +5 more 2024-01-30 $240,236,000
11685777 Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca +5 more 2023-06-27 $651,597,000
11104724 Compositions and methods for antibodies targeting staphylococcal leukotoxins Victor J. Torres, Anthony Lynch, Peter T. BUCKLEY 2021-08-31
10562968 Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca +5 more 2020-02-18 $144,579,000